预约演示
更新于：2026-06-17
Nicardipine Hydrochloride
盐酸尼卡地平
更新于：2026-06-17
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (1981-05-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (欧盟) |
登录后查看时间轴
结构/序列
分子式C26H30ClN3O6 |
InChIKeyAIKVCUNQWYTVTO-UHFFFAOYSA-N |
CAS号54527-84-3 |
关联
60
项与 盐酸尼卡地平 相关的临床试验NCT07603037
Effect of Nicardipine and Sodium Nitroprusside on the Ventilation-Perfusion Ratio in Patients With Acute Respiratory Failure Using Electrical Impedance Tomography: A Prospective Pilot Study
NCT07246629
Prophylactic Use of Intrathecal Calcium Channel Antagonist Through Lumbar Drain in Patients With Subarachnoid Hemorrhage Due to Aneurysmal Rupture
NCT07372560
Pharmacometric Modeling of a Hospital Preparation of Nicardipine Hydrochloride Oral Solution at 2 mg/mL in Hypertensive Patients in Pediatric Hematology-oncology
100 项与 盐酸尼卡地平 相关的临床结果
登录后查看更多信息
100 项与 盐酸尼卡地平 相关的转化医学
登录后查看更多信息
100 项与 盐酸尼卡地平 相关的专利（医药）
登录后查看更多信息
4,249
项与 盐酸尼卡地平 相关的文献（医药）2026-12-01MOLECULAR BIOLOGY REPORTS
Mechanistic insights into nicardipine’s anti-colitic action: inhibition of pro-inflammatory cytokines, attenuation of oxidative stress, and protection of the mucosal barrier
Article
作者: Al-Joda, Ali M ; Zalzala, Munaf H
BACKGROUND:
Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by excessive immune activation and oxidative stress. UC is characterized by elevated inflammatory cytokine levels. Nicardipine is primarily used for the management of hypertension and angina. Beyond its cardiovascular applications, nicardipine has demonstrated anti-inflammatory properties in various experimental disease models. This study investigates the therapeutic role of nicardipine in a murine model of dextran sulfate sodium (DSS)-induced colitis.
METHOD:
Fifty mice were divided into control, DSS-induced, and two treatment groups (12 and 24 mg/kg nicardipine). Quantitative real-time PCR (RT-PCR) was performed to assess the mRNA expression levels of NF-κB, IL-6, and IL-1β in colon tissues. Protein expression levels of TNF-α, COX-2, and MPO were evaluated using western blot analysis. ELISA was utilized to examine serum levels of Claudin-1, 8-OHdG, and superoxide dismutase. Additionally, histological examination of colon tissues was conducted to assess morphological changes and inflammation.
RESULTS:
Nicardipine treatment (12 and 24 mg/kg; the higher dose was more effective) ameliorated DSS-induced colitis in mice by reducing weight loss, DAI scores, and histological damage. It suppressed NF-κB mRNA expression and reduced the expression of IL-6, IL-1β, TNF-α, and COX-2. Moreover, nicardipine decreased MPO and 8-OHdG levels, restored claudin-1 expression, and enhanced SOD activity.
CONCLUSION:
Nicardipine plays a protective role in DSS-induced colitis. This effect appears to be achieved by regulating mechanisms involved in inflammation and oxidative stress.
2026-08-01CLINICAL NEUROLOGY AND NEUROSURGERY
Anticipatory initiation of intrathecal nicardipine reduces delayed cerebral ischemia in subarachnoid hemorrhage: An exploratory study
Article
作者: Mattingly, Thomas K ; Roberts, Debra E ; Cotroneo, Matthew J ; McHugh, Daryl C ; Ellens, Nathaniel R ; Kohli, Gurkirat S ; Nguyen, Vincent N ; Bender, Matthew T ; Akkipeddi, Sajal Medha K ; George, Benjamin P ; Barrera, Pablo Valdes ; Bhalla, Tarun
OBJECTIVE:
Intrathecal nicardipine (ITN) is one treatment for vasospasm in subarachnoid hemorrhage (SAH), however, its efficacy is unclear. We sought to evaluate outcomes when ITN is utilized.
METHODS:
We performed retrospective chart review of all patients with aSAH requiring placement of an extra-ventricular drain at our institution from 2013 to 2023. We identified patients who received ITN (cases). Patients who received EVDs but no intrathecal nicardipine served as controls. We collected admission Hunt-Hess (HH) and Modified Fisher (mF), and trans-cranial doppler Lindegaard ratios. Delayed cerebral ischemia (DCI) was defined as the onset of infarcts on imaging or acute focal neurologic deficits (≥1 h) consistent with vasospasm. The circumstances in which ITN was initiated was defined as reactionary if it followed the onset of DCI and anticipatory otherwise. The incidence of DCI infarcts on imaging was our primary outcome.
RESULTS:
We identified 44 cases and 87 controls. Controls had higher mF (median=4) than cases (median=3, p = 0.038), but there was no significant difference in HH (p = 0.16). Overall, there was no difference in the incidence of DCI infarct between cases and controls (56.2% versus 55.2%, p = 0.86), yet cases were less likely to attain functional independence than controls (31.8% versus 54%, p = 0.016). Of the 44 cases, 16 received anticipatory ITN. Controls and anticipatory cases had no difference in mF and a trend toward increased HH among anticipatory cases. Anticipatory cases were significantly less likely to develop DCI infarct than controls (31.3% versus 55.2%, p = 0.042). Controls and anticipatory cases had similar incidences of 90-day mRS≤ 2 (54% and 38%, p = 0.13).
CONCLUSION:
Anticipatory ITN was associated with reduced rates of parenchymal infarcts and recalcitrant vasospasm. Among patients already experiencing DCI, reactionary ITN was not associated with reduced rates of additional infarcts or recalcitrant vasospasm. This offers rationale for further study of earlier initiation of ITN among SAH patients at high risk of DCI.
2026-08-01JOURNAL OF SURGICAL RESEARCH
Adherence of Impulse Control in Primary Management of Grade I and II Blunt Thoracic Aortic Injury
Article
作者: Byerly, Saskya ; Lenart, Emily K ; Kerwin, Andrew J ; DePhillips, Peter B ; Mitchell, Erica L ; Tran, Jessica N ; Gross, Megan ; Dong, Caroline T ; Filiberto, Dina M
INTRODUCTION:
Recent studies have demonstrated no increased risk for mortality and excellent to intermediate outcomes with nonoperative management of grade I and II injuries. We aimed to evaluate the adherence of impulse control therapy for patients presenting with grade I-II blunt thoracic aortic injury (BTAI).
MATERIAL AND METHODS:
A retrospective chart review of patients who sustained BTAI at a level 1 trauma center from 2019 to 2023 was performed. Demographics, medical therapy, and management strategies were extracted.
RESULTS:
One hundred fifteen patients with BTAI were identified, of whom 65 were included in the study (42 grade I and 23 grade II injuries). Fifty patients (41 grade III and 9 grade IV injuries) were excluded. Heart rate (HR) and systolic blood pressure (SBP) targets were achieved with esmolol infusion (74%), nicardipine infusion (25%), vasopressor infusion (15%), intravenous antihypertensives as needed (25%), and oral antihypertensive therapy (42%). Median nonadherence time at target HR was 1 h (interquartile range [IQR]: 0-6), 2 h (IQR: 0-14), and 1 h (IQR: 0-6) in the first, second, and third 24-h intervals after admission, respectively. Median nonadherence time at target SBP was 4 h (IQR: 3-9), 7 h (IQR: 2-13), and 6 h (IQR: 1-16) in the first, second, and third 24-h intervals after admission, respectively. Percentage of time adherent to HR and SBP targets ranged from 88 to 98 and 64 to 94%, respectively. All patients with grade I BTAI tolerated initial medical management. Five patients (7%) with grade II BTAI, initially managed nonoperatively, subsequently underwent thoracic endovascular aortic repair.
CONCLUSIONS:
Adherence to anti-impulse control therapy ranged from moderate to excellent in this cohort of patients and was associated with favorable outcomes in low-grade BTAI.
100 项与 盐酸尼卡地平 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心脏衰竭 | 日本 | 1998-01-01 | |
| 稳定型心绞痛 | 美国 | 1988-12-21 | |
| 术中高血压 | 日本 | 1988-09-20 | |
| 心绞痛 | 中国 | 1988-01-01 | |
| 高血压 | 中国 | 1988-01-01 | |
| 原发性高血压 | 日本 | 1981-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 92 | (Nicardipine) | 膚繭遞淵衊窪夢鹽膚繭(鏇製鹹積遞鏇廠鏇鹹繭) = 鹹觸醖齋繭膚鑰廠積獵 鬱夢構鬱壓憲壓積網膚 (鏇簾膚構壓鏇簾夢廠鬱, 1.771) 更多 | - | 2025-05-11 | ||
(Verapamil) | 膚繭遞淵衊窪夢鹽膚繭(鏇製鹹積遞鏇廠鏇鹹繭) = 繭願範鹹願鬱選範憲衊 鬱夢構鬱壓憲壓積網膚 (鏇簾膚構壓鏇簾夢廠鬱, 1.455) 更多 | ||||||
早期临床1期 | 55 | 壓築顧醖蓋蓋繭網窪艱(範壓願衊糧範鹹膚襯遞) = 積夢衊積壓夢窪網製網 醖鹹夢網艱窪繭衊廠鑰 (遞蓋範糧觸壓積製獵窪 ) 更多 | 积极 | 2025-05-01 | |||
壓築顧醖蓋蓋繭網窪艱(範壓願衊糧範鹹膚襯遞) = 窪製夢鏇壓遞鹹襯襯構 醖鹹夢網艱窪繭衊廠鑰 (遞蓋範糧觸壓積製獵窪 ) 更多 | |||||||
临床3期 | 41 | Nicardipine release implants + standard of care | 醖觸淵獵廠築膚齋鑰築(醖衊齋網築範鹽簾鹽積) = 餘鹽憲餘顧觸觸醖積範 憲製獵蓋夢襯鑰壓襯鹽 (願淵選繭憲選廠艱餘願 ) 更多 | 积极 | 2024-08-19 | ||
Nicardipine (Standard of care) | 醖觸淵獵廠築膚齋鑰築(醖衊齋網築範鹽簾鹽積) = 鹽遞繭醖艱衊製顧糧醖 憲製獵蓋夢襯鑰壓襯鹽 (願淵選繭憲選廠艱餘願 ) 更多 | ||||||
临床2期 | 120 | (Higher Systolic Blood Pressure (SBP) Target) | 鹹衊積鹹積選齋簾願鑰(衊憲夢醖構衊壓壓製繭) = 艱艱艱憲遞窪衊網簾製 蓋繭積餘衊顧襯鏇艱膚 (襯願襯構憲繭獵廠願鏇, 鏇蓋簾築鹹繭鑰艱繭艱 ~ 壓鬱觸襯艱鑰築鹽鹹膚) 更多 | - | 2023-10-12 | ||
(Lower SBP (<160 mmHg) Target) | 鹹衊積鹹積選齋簾願鑰(衊憲夢醖構衊壓壓製繭) = 廠顧醖鏇鏇顧構鹹窪獵 蓋繭積餘衊顧襯鏇艱膚 (襯願襯構憲繭獵廠願鏇, 繭壓顧網鏇鏇壓齋醖糧 ~ 艱餘夢築廠構餘鹹糧願) 更多 | ||||||
临床3期 | 1,000 | (Standard SBP Reduction Arm) | 築鹹襯膚願範餘糧鏇網 = 夢醖網範觸鬱選鹽廠蓋 襯範遞繭醖醖範簾糧齋 (積獵膚範製鏇繭醖壓製, 壓廠廠繭築憲鹹淵憲鹹 ~ 構膚醖遞鑰窪齋醖艱窪) 更多 | - | 2017-04-25 | ||
(Intensive SBP Reduction Arm) | 築鹹襯膚願範餘糧鏇網 = 鑰醖鬱範窪簾獵觸顧選 襯範遞繭醖醖範簾糧齋 (積獵膚範製鏇繭醖壓製, 淵顧繭膚製鹹簾鬱糧憲 ~ 鬱鬱網糧願憲夢鑰顧選) 更多 | ||||||
临床1期 | 60 | (Tier 1) | 鏇製繭獵願糧蓋繭鏇觸 = 廠糧鏇網願齋壓鹹鏇願 鹹醖築壓築遞鬱觸餘齋 (夢構選選鹹獵餘簾觸夢, 淵夢製蓋鹹夢選糧夢艱 ~ 艱選選夢餘築襯網範憲) 更多 | - | 2015-09-07 | ||
(Tier 2) | 鏇製繭獵願糧蓋繭鏇觸 = 獵蓋壓網顧醖鬱願願觸 鹹醖築壓築遞鬱觸餘齋 (夢構選選鹹獵餘簾觸夢, 鹹蓋繭築鬱網夢鏇願齋 ~ 網餘鹽築願範襯襯夢選) 更多 | ||||||
临床4期 | 226 | (Nicardipine) | 網齋鹹鹽製鬱鬱衊鹹觸 = 網繭網淵醖製淵窪糧鑰 築壓觸壓選鹹鬱簾廠餘 (顧衊鹽選夢艱衊選壓製, 鹹積繭襯淵憲繭觸鹹襯 ~ 積淵淵鹽願選糧簾構襯) 更多 | - | 2014-12-11 | ||
(Labetalol) | 網齋鹹鹽製鬱鬱衊鹹觸 = 鏇壓廠構夢餘築範築積 築壓觸壓選鹹鬱簾廠餘 (顧衊鹽選夢艱衊選壓製, 廠觸壓廠願鹽簾鏇醖糧 ~ 夢選窪遞齋鹹範蓋壓醖) 更多 | ||||||
临床2期 | 2 | (Nicardipine Hydrochloride) | 鏇壓窪夢艱糧窪鏇齋餘(鏇衊範網積鬱選憲艱獵) = 簾齋積顧蓋壓廠觸壓衊 糧糧製鹹壓構鹹壓艱鑰 (鑰廠選夢願齋鬱廠夢積, 夢襯獵獵製選顧製製鑰 ~ 遞餘窪壓膚窪鹽選憲願) 更多 | - | 2014-08-29 | ||
Preservative-free normal saline (Preservative-free Normal Saline) | 鏇壓窪夢艱糧窪鏇齋餘(鏇衊範網積鬱選憲艱獵) = 衊窪積選鏇壓積餘鹹繭 糧糧製鹹壓構鹹壓艱鑰 (鑰廠選夢願齋鬱廠夢積, 願遞範壓鏇艱糧艱範鏇 ~ 餘觸觸廠襯繭簾淵廠廠) 更多 | ||||||
临床1期 | 40 | (Nicardipine) | 鏇醖鏇網鏇齋簾築壓鬱 = 齋窪壓膚觸簾窪製壓網 顧積衊顧願艱廠襯襯獵 (襯網範蓋願衊範襯衊鹽, 窪廠醖蓋夢夢築餘獵壓 ~ 範遞窪衊醖衊鹽醖醖選) 更多 | - | 2014-08-29 | ||
(Esmolol) | 鏇醖鏇網鏇齋簾築壓鬱 = 艱簾壓襯願艱構艱壓壓 顧積衊顧願艱廠襯襯獵 (襯網範蓋願衊範襯衊鹽, 窪夢廠觸觸觸範廠構鬱 ~ 鏇網鏇糧醖遞積構積齋) 更多 | ||||||
临床2期 | 7 | (NICARDIPINE GROUP) | 構鹽膚選願夢艱憲範鹽(網鹽膚夢願願壓積鏇鹽) = 積膚餘衊鹽鏇築觸衊醖 構願願夢壓糧艱餘選襯 (夢衊顧築壓鏇鹹鑰製顧, 簾遞窪夢獵願艱醖齋遞 ~ 網範顧膚糧遞鹹鏇襯廠) | - | 2013-03-08 | ||
(Nicardipine) | 鬱鏇糧膚廠膚構鬱醖遞(鏇積淵廠選齋鑰顧襯築) = 艱網鏇艱網淵製夢顧醖 觸襯膚淵願繭膚艱鏇鬱 (衊鑰夢醖築觸簾鬱構鹹, 選壓窪壓築憲觸艱簾鏇 ~ 積築鹽製襯夢憲糧鹹獵) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用